FIRST-IN-CLASS SMALL MOLECULE IMMUNOTHERAPIES TO TREAT SOLID CANCERS
LATEST NEWS
Kayothera Founder Presented with Princeton University’s Tiger Entrepreneur Award
Princeton Entrepreneurship Council is pleased to announce the winners of the 2022 Tiger Entrepreneur Award. For the last six years, the Tiger Entrepreneur Award has been given to celebrate the value of entrepreneurship across the Princeton community and to emphasize...
KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics
Novel Approach to Treat Late-Stage and Metastatic Cancers SEATTLE, WA – March 16, 2022, KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing novel cancer immunotherapies, today announces the closing of an $8 million Series A round of...
KayoThera selected as a finalist in TechUnited’s Propelify Event
Kayothera was selected as one of four finalists in this year's Propelify event, a premier event celebrating technology and innovation in the tri-state area. Kayothera will be pitching at the BetterWellness challenge at 1:10 pm on October 6. The judges will award two...
BIO Announces KayoThera as the 2021 Start-up Stadium Winner
The Biotechnology Innovation Organization (BIO) today announced that Kayothera Inc. is the winner of the Start-up Stadium competition held during BIO Digital in June. Pre-recorded presentation videos submitted by 16 finalists were evaluated by expert judges with...
Kayothera selected as finalist in BIO’s Start-up Stadium
Kayothera will be presenting on their novel immune oncology pipeline during the week of June 10 at BIO's annual meeting. Pitches for the Startup Stadium will go live on Thursday followed by voting.
KayoThera to graduate from Endless Frontier Labs Accelerator
KayoThera has taken part in the NYU Stern Business School Endless Frontier Labs accelerator program since October 2020 to refine the business plan and expand the company trajectory and growth initiatives. This accelerator was exceptionally valuable to the development...
KayoThera founders publish Nature Cancer review on new therapeutic strategies to treat incurable cancers
Announcing a new review on emerging strategies to treat advanced cancers published in Nature Cancer.
KayoThera founders announce discovery of a new organelle driving cancer metastasis
In the cover article of the March issue of Nature Cell Biology, Dr. Mark Esposito and Dr. Yibin Kang announce the discovery of a novel driver of breast and prostate cancer metastasis. This newly discovered organelle is driven by a relatively unknown protein named...
KayoThera will present at BioNJ’s 10th Annual Biopartnering conference
KayoThera will be presenting at this year's 10th Annual BioNJ Biopartnering Conference. Please join us Tuesday, October 6 & Wednesday, October 7, 2020.
KayoThera launches with Seed Funding Round from NJHF
Kayothera, an early-stage therapeutics company and Princeton University spinout, is working to give hope to some of the most vulnerable cancer patients. Now the company’s aspirations are being bolstered by significant seed funding received from the New Jersey Health...